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RANDOMIZED CONTROLLED TRIALThe Important Role for Intravenous Iron in Perioperative Patient
Blood Management in Major Abdominal Surgery
A Randomized Controlled TrialBernd Froessler, MD, MClinSc,y Peter Palm, MD, Ingo Weber, MD, Nicolette A. Hodyl, PhD,z
Rajvinder Singh, MBBS, MPhil,§ and Elizabeth M. Murphy, PhDjjObjective: To determine if preoperative intravenous (IV) iron improves
outcomes in abdominal surgery patients.
Summary Background Data: Preoperative iron deficiency anemia (IDA)
occurs frequently; however if left untreated, increases the risk of blood
transfusion allogeneic blood transfusion (ABT). Limited evidence supports
IDA treatment with preoperative IV iron. This randomized controlled trial
aimed to determine whether perioperative IV iron reduced the need for ABT.
Methods: Between August 2011 and November 2014, 72 patients with IDA
were assigned to receive either IV iron or usual care. The primary endpoint
was incidence of ABT. Secondary endpoints were various hemoglobin (Hb)
levels, change in Hb between time points, length of stay, iron status, morbid-
ity, mortality, and quality of life 4 weeks postsurgery.
Results: A 60% reduction in ABTwas observed in the IViron group compared
with the usual care group (31.25% vs 12.5%). Hb values, although similar at
randomization, improved by 0.8 g/dL with IViron compared with 0.1 g/dL with
usual care (P¼ 0.01) by the day of admission. The IViron group had higher Hb 4
weeks after discharge compared with the usual care group (1.9 vs 0.9 g/dL, P¼
0.01), and a shorter length of stay (7.0 vs 9.7 d, P ¼ 0.026). There was no
difference in discharge Hb levels, morbidity, mortality, or quality of life.
Conclusions: Administration of perioperative IViron reduces the need for blood
transfusion, and is associated with a shorter hospital stay, enhanced restoration of
iron stores, and a higher mean Hb concentration 4 weeks after surgery.
Keywords: intravenous iron, iron deficiency anemia, outcomes, red blood
cell transfusion, surgery
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Annals of Surgery  Volume 264, Number 1, July 2016ron deficiency (ID) and iron deficiency anemia (IDA) are commonI conditions affecting a quarter of the world’s population.1 Aside
from age, socioeconomic circumstances, poor nutrition, and preg-
nancy, many pathological states frequently lead to iron depletion.
In patients presenting for noncardiac surgery, ID with or
without anemia is found in up to 39% of patients.2 In
certain subgroups, like colorectal cancer or patients with heavy
menstrual bleeding, the occurrence of preoperative anemia has
been found to be as high as 57 %.3,4 The cause of the ID is either
disease related, for which the patient is being treated, or therapy
related, as for many individuals on nonsteroidal anti-inflammatory
drugs.5
Anemia, ABT, and perioperative significant blood loss have
all been established as adversely impacting clinical outcomes.6
Perioperatively, anemic patients frequently are exposed to alloge-
neic transfusion events, increased rates of infections, increased
numbers of cardiac complications, an increased number of days
in hospital, and more deaths.2,7–9 Anemia is often corrected by
ABT, despite the evidence that even small amounts of transfused
allogeneic red cells have a significant negative effect on morbidity,
mortality,10 and reduces cancer-related survival and overall
survival in colorectal cancer patients.9 Transfusion-associated
hazards and the noninferiority of restrictive transfusion approaches
have been demonstrated, challenging traditional transfusion
practice.11–13
Comprehensive patient blood management (PBM) programs
offering effective approaches for minimizing perioperative blood
loss and optimized patient care have been designed and implemented
in some countries.14,15 However, due to evidence gaps, translational
delays for existing evidence, and ongoing skepticism, transfusion
practices continue to vary considerably among clinicians.16 Preop-
erative optimization of anemia seems to be a key aspect of
PBM.6,16,17 In particular, patients scheduled for major surgery and
with medical conditions often associated with ID should be assessed
at least 4 weeks before surgery to allow clinicians to interpret blood
results with a window of opportunity to act and correct reversible
hemopoietic deficiencies.17–19
Both oral and IV iron have been shown to correct ID and
IDA,20,21 but neither has become standard practice,22 nor has the
ideal timing of preoperative intervention for IV iron been deter-
mined.20,23 Oral iron replacement is in many instances poorly
tolerated, ineffective, or even detrimental.24,25,26 There is increasing
evidence that in select patient groups presenting for elective surgery
and in urgent cases, treatment with IV iron might benefit the patient
and should result in a reduction of RBC transfusion and transfusion-
related adverse events.17,27 Should an increased use of IV iron for at-
risk patients have the predicted effect of improved hematological
parameters and restored iron levels, the impact would translate to
significant benefits for the individual in the immediate postoperative
period and the weeks after hospital discharge.er Health, Inc. All rights reserved.
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This was a randomized controlled trial. The protocol was
approved by the study hospital’s human research ethics committee
and registered with the Australian New Zealand Clinical Trials
Registry (ACTRN12611000387921).
We randomly allocated participants (1:1) to either perioper-
ative intravenous (IV) iron administration (intervention) or usual
care. Randomization followed a computer-generated number
sequence and allocation was conducted by telephone. The surgeon
performing the operation was informed of patient participation in the
study but group allocation was not revealed.
We screened 626 patients scheduled for abdominal surgery for
the presence of IDA between August 2011 and November 2014.
After informed written consent, patients eligible for inclusion (>18
yrs with IDA, ferritin <300 mcg/L, transferrin saturation <25%, Hb
<12.0 g/dL for women, Hb <13.0 g/dL for men) were randomized
between 4 and 21 days before surgery into 2 groups. Owing to this
wide range in the preoperative period between patients, a standard
approach was used to assess transfusion events in the preoperative
period, including any transfusion administered in the 21 days before
surgery. Patients in the intervention group received IV ferric carbox-
ymaltose, given as a single dose over 15 minutes, before surgery
(simplified dosing protocol; 15 mg/kg bodyweight to a maximum
dose of 1000 mg). Postoperatively, within 2 days of surgery, inter-
vention group participants received 0.5 mg of ferric carboxymaltose
per recorded 1 mL of blood loss, if blood loss was at least 100 mL.
Blood loss was measured as accurately as possible by recording
suction bottle volume and weighing packs at the end of the operation.
Patients in the usual care group received perioperative care, including
anemia management, provided by the primary care physician or
surgical home team. Usual care provided included no treatment,
continued observations, oral iron recommendations, and ABT. At the
time of initiation of the study, IV iron was not considered usual care;
however, prescription and administration was not disallowed.
In the institution, the prescription and administration of the
intervention was facilitated by the anesthetic team. Baseline testing
of the Short Form Health Survey (SF36) was conducted at study
entry.28
Follow-up of participants was scheduled for 4 weeks after
surgery. The SF36 and screening bloods were repeated at this time.
Patients found to have noteworthy ID or IDA at follow-up, irre-
spective of group allocation, were referred to their General Prac-






Age 64 15 68 15
Height, cm 166 10 167 10
Weight, kg 86 27 88 20
BMI, kg/m2 30 8 31 7
ASA 2 17 (42.5) 17 (53.1)
ASA 3 22 (55) 15 (46.9)
ASA 4 1 (2.5) 0
Sex (male/female) 19/21 17/15
Surgery
Days before surgery 8 (6–13) 10 (5–15)
Estimated blood loss during surgery 360 (200–700) 300 (100–512)
Data are median (IQR).
BMI indicates body mass index; ASA, physical status classification system; IQR,
interquartile range.Quality Control Procedure
A trial information session was given to the departmental
members involved before commencing the study. Regular refreshers
were scheduled to assure protocol knowledge and adherence. The
multidisciplinary composition of the research team facilitated this
process. Follow-up and data entry were meticulously conducted by a
research assistant, and primary care physician follow-up and care
initiated when necessary to assure patient safety.
Outcomes
The primary endpoint was incidence of ABT. Secondary
endpoints included hemoglobin (Hb) on admission, Hb difference
from randomization to admission, ICU admission, perioperative
morbidity (defined as new onset infection, respiratory failure, renal
impairment, deep venous thrombosis), discharge Hb, length of stay,
Hb at follow-up, Hb difference from discharge to follow-up, iron
status, 30-day mortality, and quality of life (QoL). QoL score
was scaled from 36 to 160, with lower scores reflecting poorer
well-being. Copyright © 2016 Wolters Kluw
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The sample size of this study was calculated for the primary
outcome parameter (perioperative allogeneic transfusion event). To
reduce the risk of a perioperative allogeneic transfusion event from
30% to 15% (a 50% risk reduction) with a power of b ¼ 0.8 and a
significance level of a ¼ 0.05, it was determined that a total of 121
patients in each group would be needed. To account for possible
dropouts, we intended to include 134 patients per group. The power
calculation was performed using nQuery Advisor Version 7.0 (Stat-
istical Solutions, Saugus, MA). Parametric data were tested with one-
way ANOVA, and are presented as mean and standard error of the
mean or as mean and 95% confidence intervals. Nonparametric data
were tested with Mann-Whitney U tests, and are reported as either
median (IQR) or median (minimum–maximum), as indicated.
Categorical data were analyzed with the 2-tailed Pearson x2 test,
and are presented accordingly as number and percent of total.
Statistical analysis was performed using SPSS software version
17.0 (SPSS Inc, Chicago, IL).RESULTS
An early interim data analysis was requested following con-
cerns raised by the clinical investigator team after high rates of RBC
transfusion, considered to be an independent risk factor for adverse
clinical outcomes, noted after the 4-week follow-up in a subset of
patients. This was performed by an independent statistician on the
interim data-monitoring committee with the data blinded (interven-
tion group n¼ 32, usual care group n¼ 26). The results of the interim
analysis were forwarded to 2 independent experts in the field to
assess safety concerns. Enrolment continued while waiting for a
response. There was disagreement among the assessors, and a third
independent expert opinion was sought. Based on advice from 2 of
the 3 independent experts, the study was terminated early due to
higher than expected rates of poor outcome in the usual care group.
At the time of study termination, 72 eligible patients were
enrolled and randomized (intervention group n ¼ 40, usual care
group n ¼ 32) (see Supplemental Digital Content eFigure 1). Group
characteristics are shown in Table 1, and the type of surgery for the
patient groups is shown in Supplementary Table 1, http://links.
lww.com/SLA/A967. Cancer was the underlying condition in 73%
of group 1 patients and 85% of patients in the usual care group.
The overall transfusion rate in the study was 20.8%. Ten patients iner Health, Inc. All rights reserved.
 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 2. Primary Outcome; Perioperative Red Blood Cell Transfusions
Transfusion Events Occurring in Each Period Intervention n ¼ 40 Usual Care n ¼ 32 P
Preoperative 0 2 (6%) 0.190
Units transfused 0 7
Intraoperative 0 5 (16%) 0.014
Units transfused n.a. 7
Postoperative 5 (12%) 10 (31%) 0.079
Units transfused 8 18
Total number of Patients transfused 5 (12.5%) 10 (31.25%) 0.079
Units transfused 8 32
Total number of transfusion events 5 17 <0.001
Total units/patient (median, minimum–maximum) 0 (0–2) 0 (0–5) 0.021
Total units/transfused patient (median, minimum–maximum) 2 (1–2) 3 (2–5) 0.016
Transfusion events presented in the table are differentiated into time of transfusion and total events experienced in the perioperative period. The preoperative period was defined as
the 3 weeks before surgery; data are n (%) unless otherwise stated.
Annals of Surgery  Volume 264, Number 1, July 2016 Intravenous Iron, Surgery, Transfusionthe usual care group (10/32 ¼ 31.25%) were transfused vs 5 in the
intervention group (5/40 ¼ 12.5%), equating to a 60% relative
reduction in transfusions between the 2 groups shown in Table 2.
There were no intraoperative RBC transfusions in the intervention
group compared with 5 in the usual care group (P ¼ 0.014) and a
significant reduction in the number of total perioperative ABT events
in group 1 (5/40, 12.5 %) compared with group 2 (17/32, 53 %), P <
0.0003. The median number of units per transfused patient was also
decreased in the intervention group (2 compared with 3 in the usual
care group; P ¼ 0.016; Table 2). There was no difference in the
rationale for transfusion between the 2 groups with the majority
being performed due to low hemoglobin (Supplementary Table 2,
http://links.lww.com/SLA/A967). The median IV iron dose admin-
istered to participants in the intervention group was 1200 mg (IQR
1088–1363). Five participants in the usual care group were given a
median IV iron dose of 1800 mg (IQR 1467–2000). Any participant
receiving IV iron had a maximum of 2 infusions. No serious adverse
event resulted from the iron infusion. Three participants suffered the
following mild adverse events: headache, light-headedness, and back
pain. The latter settled with simple analgesics. Hb levels across study
period and other important secondary outcome parameters are shown
in Tables 3 and 4. Hb values were not different at randomization and
improved by 0.8 g/dL in group 1 and by 0.1 g/dL in the usual care Copyright © 2016 Wolters Kluw





Difference between randomization and admission 0.8 0
Discharge 10.3 1
4 wk 12.2 1
Postdischarge change (4 wk minus discharge value) 1.9 1
Iron statusy
Ferritin at randomization, mg/L 19 (6–48
Ferritin at 4 wk, mg/L 248 (137–
Transferrin saturation at randomization, % 6 (3–10
Transferrin saturation at 4 wk, % 21 (16–2
CRPy
CRP at randomization, mg/L 7.2 (2.9–
CRP at 4 wk, mg/L 5.8 (2.3–
Sample size varies due to missing values at each time point.
Data presented as meanSD.
yData are expressed as median (IQR).
 2016 Wolters Kluwer Health, Inc. All rights reserved.group (P¼ 0.01) by the day of admission. Despite higher transfusion
rate in the usual care group, there were no differences between groups
in discharge Hb (10.3 vs 10.2 g/dL for the intervention group and
usual care group, respectively). However, Hb increased by 1.9 g/dL
in the intervention group and 0.9 g/dL in the usual care group (P ¼
0.01) from the time of discharge to follow-up and was significantly
higher at 4 weeks postsurgery (12.2 g/dL compared with 11.1 g/dL in
the usual care group, P < 0.001). Length of stay was shortened by 3
days in the intervention group compared with the usual care group (6
vs 9 d, P¼ 0.05). There was no significant difference in morbidity or
mortality (Table 4). QoL scores were higher at baseline for the
intervention group; however, score reduction was equal between
the groups.
DISCUSSION
This first RCTon managing preoperative anemia in abdominal
surgery, involving only patients with confirmed IDA, demonstrates
the important role for IV iron in perioperative PBM. The results also
highlight the ongoing mismanagement of a treatable condition
despite the well-known negative impact of IDA.29,30 In addition,
it also confirms the ongoing overuse of ABT as a default treatment
approach31–33 regardless of the well-described transfusion-related
risks34 and the safety of restrictive transfusion practices.10,12,13 Weer Health, Inc. All rights reserved.
dy Period
tion n ¼ 40 Usual Care n ¼ 32 P
.3, n ¼ 40 10.6 1.4, n ¼ 32 0.76
.3, n ¼ 36 10.7 1.7, n ¼ 29 0.12
.8, n ¼ 36 0.1 1.3, n ¼ 29 0.01
.3, n ¼ 37 10.2 0.9, n ¼ 31 0.31
.2, n ¼ 36 11.1 1.2, n ¼ 28 <0.001
.4, n ¼ 36 0.9 1.4, n ¼ 28 0.01
), n ¼ 40 37 (11–82), n ¼ 32 0.06
546), n ¼ 36 99 (35–228), n ¼ 27 0.002
), n ¼ 40 9 (7–15), n ¼ 32 0.03
6), n ¼ 36 14 (7–18), n ¼ 27 0.003
19.3), n ¼ 40 7.7 (2.6–16.8), n ¼ 32 0.99
12.6), n ¼ 36 11 (3.1–23), n ¼ 27 0.18
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TABLE 4. Other Secondary Outcomes of Interest
Intervention n ¼ 40 Usual Care n ¼ 32 P
Length of stay, d 6 (1–19) 9 (1–23) 0.05
Infectiony 4 (10%) 5 (16%) 0.5
Respiratory failurey 3 (7.5%) 3 (9%) 0.99
Renal impairmenty 1 (2.5%) 1 (3%) 0.99
DVTy 0 1 (3%) 0.45
Readmissiony 6 (15%) 3 (9%) 0.72
Discharged on oral irony 5 (12.5%) 1 (3%) 0.22
Deathy 1 (2.5%) 0 0.99
QoL (presurgery/intervention)z 104 15 96 18 0.02
QoL (4 wk postsurgery)z 96 14 90 26 0.24
Difference in QoL (pre–post)z 8 18 6 17 0.70
QoL score scale; 36–160, lower scores reflecting poorer well-being.
Median (minimum–maximum).
yData are n (%).
zData are expressed as meanSD unless otherwise stated.
Froessler et al Annals of Surgery  Volume 264, Number 1, July 2016also report that although Hb levels were equivalent in the 2 groups at
discharge, they were 1 g/dL higher in the treatment group compared
with the usual care group at 4 weeks after surgery. This demonstrates
that perioperative iron repletion has substantial benefit in the post-
operative recovery period, potentially due to the iron repletion
allowing bone marrow to increase erythropoiesis, compared with
transfused RBCs which are rapidly cleared from the circulation and
have a shorter lifespan than normal RBCs.35 The superiority of IV
iron over oral or no iron in reducing ABT was previously demon-
strated in other clinical setting and extensively discussed in a recent
review by Mun˜oz.36
Transfusion triggers and the appropriateness of ABT admin-
istration were the focus of perioperative transfusion management at
the time when we designed this study. Our aim was to determine
whether perioperative IV iron, administered within 4 to 21 days
before substantial abdominal surgery, would lead to a significant
reduction in transfusion events. We anticipated that we would
demonstrate that this intervention would not only obviate ABT,
but also correct underlying iron deficits, facilitating better recovery
and outcomes. Since the commencement of our study, the importance
of correcting preoperative ID has been more widely accepted as an
appropriate standard of care, strengthening our hypothesis.6,17,18,21,37
The value of preoperative correction of IDA has thus become a
cornerstone of PBM guidelines around the world.14,15,38
However, data monitoring of our participants indicated that a
large proportion of enrolled subjects in the usual care group were
transfused with RBC to correct anemia but received no treatment for
their ID. RBC transfusion is considered to be an independent risk
factor for adverse clinical outcomes.10,31,39 Recognition of this
situation and the ethical responsibility to our participants prompted
an interim analysis, and the seeking of advice from impartial experts
to assess whether early termination of the study was recommended
scientifically and ethically. Enrolment in the study continued during
the assessment and decision-making process. After definitive
analysis of the expert opinion, it was deemed that the study should
be terminated in the interest of the patients.
As early as 1985, influenced by the AIDS epidemic, strategies
for avoiding or minimizing ABT were published.40 Compelling
evidence on the importance of anemia and blood management from
the last 15 years 13,37,41 put PBM on the agenda and illustrated how
PBM should be carried out. Logically, one would expect that ‘‘stand-
ard care’’ had moved on. However, our results show that the trans-
lational gap is huge and that anemia management has some way to go
in clinical practice.19,33,34,42–45 Copyright © 2016 Wolters Kluw
44 | www.annalsofsurgery.comThe assessment of adequate iron stores can be difficult. With
ferritin levels influenced by chronic disease and/or inflammation, ID
may be masked. Therefore, screened subjects were included with
ferritin levels of less than 300 mcg/L in our study, as recommended in
a consensus statement on the role of IV iron in perioperative anemia
management.46 The distribution of ferritin levels was essentially the
same in the 2 groups of participants; 48% (intervention) and 40%
(usual care) presented with profound ID, demonstrated by ferritin
levels less than 30 mcg/L. Despite sometimes longstanding and
previously diagnosed IDA, only 3 patients in our entire cohort
had been prescribed oral iron replacement therapy within the 6
weeks before surgery. Only 1 patient in the usual care group was
treated with IV iron pre- and postoperatively, and 4 received IV iron
while in hospital. IV iron was not considered usual care, at the time of
study commencement, nonetheless was not prohibited. Patients were
randomized in our study between 8 and 10 days before admission.
Although it is desirable for ID to be corrected in a timely manner, the
study establishes that a successful ‘‘rescue’’ intervention is available
and effective at a later stage, even for those with profound IDA. Our
results support a proposed ‘‘opportunity’’ approach, discussed in a
recent review article by Mun˜oz et al, and suggested earlier based on
results from pooled data by the same author.17,47
In addition to risk minimization and outcome improvement, our
findings might have significant economic implications. According to
the Australian Institute of Health and Welfare, 15,840 patients were
diagnosed with bowel cancer in Australia in 2012 and many had to
undergo abdominal surgery. Cancer patients made up the majority of
our cohort. The patients randomized to receive pre- and postoperative
IViron left hospital 3 days earlier. We suggest that this earlier discharge
was due to treatment of ID with IViron, thus minimizing the associated
risks of this exposure. Although a cost analysis was beyond the scope of
this research, we propose that this would result in a significant cost
savings, offsetting the initial expenditure of screening.
Limitations
Early termination is the main limitation of our study. However,
ethical concerns were paramount, and we made the necessary decision
in the interest of our patients. Although more cases would strengthen
the statistics, it was not anticipated that the conclusions would change.
In our view it would have been unethical to have iron-deficient patients
in a control group at increased risk of receiving a blood transfusion. A
serious hazard from an ABT resulting in morbidity or mortality in a
control patient would be difficult to defend. Another limitation is that
we performed simple randomization instead of block randomization.er Health, Inc. All rights reserved.
 2016 Wolters Kluwer Health, Inc. All rights reserved.
Annals of Surgery  Volume 264, Number 1, July 2016 Intravenous Iron, Surgery, TransfusionThis was apparent at the time of the interim analysis and the final
analysis after stopping the study. Block randomization would have
achieved a more equal balance in the allocation of participants. In this
study, 5 participants randomized to the usual care group received IV
iron as part of their standard care. Although this may have influenced
the results, the final analysis between groups would then represent a
more conservative analysis of the effects of IV iron. This change in
standard care of iron deficient patients further adds clarity to the
decision for early termination.
CONCLUSIONS
In conclusion, the administration of IV iron in the perioperative
setting resulted in a significant reduction of RBC transfusion, signifi-
cant Hb improvement from the time of randomization to admission,
shorter hospital stays, and enhanced restoration of iron stores and Hb at
4 weeks after surgery. Usual care failed the majority of participating
patients, leaving them untreated with a treatable condition.
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